SCHEMBL5261625

SCHEMBL5261625

COc1cc2[nH]c(N3CCN(c4nc(C)c(C)n4C)CC3)nc(=O)c2c(C)c1OC

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DCTPP1 Q9H773 3/20 0.35
▸ KDM4E B2RXH2 2/20 0.32
▸ KMT2A Q03164 2/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ BLM P54132 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ RXFP1 Q9HBX9 1/20 0.32
▸ POLB P06746 4/20 0.31
▸ NPC1 O15118 1/20 0.31
▸ RAB9A P51151 1/20 0.31
▸ TNKS O95271 4/20 0.31
▸ TNKS2 Q9H2K2 4/20 0.31
▸ CYP19A1 P11511 1/20 0.31
▸ NQO2 P16083 1/20 0.31
▸ HSD17B10 Q99714 1/20 0.31
▸ KCNH2 Q12809 1/20 0.31
▸ GFER P55789 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5262532 0.93 DCTPP1 (0.35) DCTPP1KDM4EKMT2AMEN1ALDH1A1
SCHEMBL5264790 0.83 DCTPP1 (0.34) DCTPP1KDM4EKMT2AMEN1ALDH1A1
SCHEMBL5262020 0.81 LMNA (0.39) KDM4EKMT2AMEN1ALDH1A1MAPT
SCHEMBL5263885 0.80 DCTPP1 (0.36) DCTPP1KDM4EKMT2AMEN1ALDH1A1
SCHEMBL5265193 0.79 PDE3B (0.39) DCTPP1KDM4EKMT2AMEN1ALDH1A1
SCHEMBL5261299 0.78 TNKS (0.37) DCTPP1KMT2AMEN1TNKSTNKS2
SCHEMBL5264473 0.78 MAPT (0.44) KDM4EKMT2AMEN1ALDH1A1GAA
SCHEMBL5263654 0.78 HTR3E (0.41) DCTPP1KMT2ATNKSTNKS2KCNH2
SCHEMBL5263193 0.78 KDM4E (0.48) KDM4EKMT2AMEN1ALDH1A1GAA
SCHEMBL5262954 0.77 SUV39H2 (0.38) DCTPP1KDM4EKMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050124607-A1 5-Substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists ROCHE PALO ALTO LLC 2005-06-09 — — US claimed
EP-1644343-B1 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2007-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124607-A1 5-Substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists ADRB1, ADRA1B, ADRB2 DCTPP1 3859/4885KDM4E 3891/4885KMT2A 3011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback